Pluristem Ltd. grants United Therapeutics exclusive, worldwide rights to its allogeneic, placental-derived expanded (PLX) cells to develop and commercialize a treatment for pulmonary hypertension

Pluristem Therapeutics Inc.

Israel / Small-Cap Biopharma (<$1 billion)

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

United Therapeutics Corp.

U.S. / Mid-Cap Biopharma ($1-$50 billion)

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Terminated

Sample

01/01/2009

announced

01/01/2009

Terminated